Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (LIFE – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $1.38.
Rahimi covers the Healthcare sector, focusing on stocks such as Cytokinetics, Prothena, and aTyr Pharma. According to TipRanks, Rahimi has an average return of 1.8% and a 31.65% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for aTyr Pharma with a $21.50 average price target, implying a 1,457.97% upside from current levels. In a report released on September 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
LIFE market cap is currently $86.14M and has a P/E ratio of -1.12.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LIFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
- aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- aTyr Pharma reports Q2 EPS (22c), consensus (28c)
